Summary of Study Methodology: TLC-2716 Phase 1 Clinical Trial
This text details the methodology of a Phase 1 clinical trial investigating the safety,pharmacokinetics (PK),and pharmacodynamics of a drug called TLC-2716. Here’s a breakdown:
1. Participants:
* Inclusion: Participants were generally healthy, with some allowance for mild elevations in triglycerides (TG ≥150 mg/dL) and/or LDL-cholesterol (LDL-C ≥130 mg/dL). mild liver function abnormalities consistent with Gilbert’s Syndrome were also permitted (up to 1.5x the upper limit of normal).
* Exclusion: Several criteria excluded potential participants, including:
* Pregnancy or lactation
* High TG (≥500 mg/dL) or LDL-C (≥190 mg/dL)
* Serious medical or psychiatric illness
* Excessive alcohol or substance use
* Recent use of investigational drugs
* Most prescription and over-the-counter medications (exceptions: vitamins, acetaminophen, ibuprofen, hormonal contraceptives).
2. Study Design & Assessments:
* Exploratory Nature: The study was exploratory, meaning formal power calculations for sample size weren’t performed. Sample size was chosen to adequately characterize safety,PK,and pharmacodynamics.
* assessments:
* Safety & Tolerability: Monitored through adverse event (AE) reporting, lab tests, physical exams, and electrocardiograms. AEs were graded using CTCAE v5.0.
* Pharmacokinetics (PK): Intensive blood sampling was done to measure TLC-2716 concentrations in plasma using liquid chromatography-tandem mass spectrometry. PK parameters were calculated using phoenix WinNonlin software.
* Pharmacodynamics:
* Lipid Parameters: ApoB, triglycerides, cholesterol, LDL-C, and HDL-C were measured using NMR LipoProfile.Residual cholesterol (RC) was calculated.
* Plasma Proteins: ApoC3 and ANGPTL3 levels were measured by ELISA.
* Reverse Cholesterol Transport (RCT): Changes in the expression of ABCA1 and ABCG1 genes in peripheral blood mononuclear cells were assessed to evaluate the impact on RCT.
3. Statistical Analysis:
* hodges-lehmann Estimator: Used to calculate placebo-adjusted percentage changes in lipid parameters due to the skewed distribution of the data.
* non-parametric Tests: Wilcoxon signed-rank tests (within-group comparisons) and Mann-Whitney U-tests (between-group comparisons) were used, with Benjamini-Hochberg (BH) adjustment for multiple comparisons.
* Sex as a Variable: Sex was self-reported but not formally analyzed due to small sample sizes in each sex group.
in essence, this Phase 1 trial aimed to understand how TLC-2716 behaves in the body (PK), its effects on relevant biomarkers (pharmacodynamics), and its safety profile in humans.
Related reading